Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations
Carisma Therapeutics ( NASDAQ:CARM ) Full Year 2024 Results Key Financial Results Revenue: US$19.6m (up 32% from FY...
| Ticker |
CARM
|
| CIK | 0001485003 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 3675 MARKET STREET, SUITE 401, PHILADELPHIA, PA, 19104 |
| Website | sesenbio.com |
| Phone | 2674916422 |
| CEO | Thomas R. Cannell |
| Employees | 20 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Carisma Therapeutics Full Year 2024 Earnings: Misses ExpectationsCarisma Therapeutics ( NASDAQ:CARM ) Full Year 2024 Results Key Financial Results Revenue: US$19.6m (up 32% from FY... Carisma Therapeutics Provides Corporate UpdatesCarisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a revised operating plan focused on evaluating strategic alternatives while reducing operational cash burn. Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceCarisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences ConferenceCarisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11 at 4:40 pm ET. Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize PipelineCarisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies. This decision aligns Carisma's efforts with next-gene |